Search

Your search keyword '"Ferraro, S. M."' showing total 11 results
Start Over Author "Ferraro, S. M."
11 results on '"Ferraro, S. M."'

2. Actividad antioxidante de la melatonina sobre el hígado graso inducido por etionina en ratones

Author

Ferraro, S. M. and López-Ortega, A.

Subjects
mice, melatonina, hígado graso, estrés oxidativo, ratón, oxidative stress, melatonin, fatty liver
Abstract

The aim of this study was to determine the antioxidant activity of melatonin in female mice with ethionine-induced hepatic oxidative stress (HOS), and the effect of this hormone on the gluthatione peroxidase enzyme antioxidant activity. Twenty adult female NMRI mice were given intraperitoneally 3 mg/kg melatonin in 1% ethanol daily for 15 days, and 1% ethanol to the control group. On the 13thday of treatment, fatty liver was induced to both groups using 7.5 mg/0.02 kg ethionine. After 48 hours of food restriction, mice were sacrificed and livers dissected and sampled. Fixed tissue was used for hystopathologic analyses, and the supernatant obtained from an homogenated was used to determine concentrations of malondialdehyde (MDA), conjugate dienes (DC), triglycerides (TG) and gluthatione peroxidase enzyme (GPx). Data were processed through SPSS vlO.O for Windows using the "t" test (P ≤ 0.05), and the results were expressed as X ± SD in mg TG, nm MDA and nm DC/mg proteins and per g of humid tissue and mU/mg proteins for GPx. Concentrations of TG, MDA and DC were lower (P< 0.001), while GPx activity was higher (P ≤ 0.05) in the treated group. It is concluded that administration of MLT at the given dose reduced the induced HOS in female mice. Also, administration of the hormone reduced the fatty liver and increased GPx activity. &nbsp, La finalidad de este estudio fue determinar la actividad antioxidante de la melatonina (MLT) sobre el estrés oxidativo hepático (EOH) inducido por etionina en ratones hembras y su efecto sobre la actividad de la enzima antioxidante glutatión peroxidasa (GPx). A 20 ratones se les administró MLT disuelta en etanol al 1% en dosis de 3 mg/kg p.v. vía intraperitoneal, durante 15 días y a los controles etanol 1%. Al día 13 a ambos grupos se indujo hígado graso por inyección de etionina 7,5 mg/0,02kg. Después de 48 horas de ayuno los animales fueron sacrificados y los hígados disecados. Una muestra se utilizó para análisis histopatólogico y en el sobrenadante obtenido de un homogeneizado se determinó malondialdehído (MDA), dienos conjugados (DC), triglicéridos (TG) y la enzima GPx. Se realizó prueba "t" (P ≤ 0,05). Las concentraciones de TG, MDA y DC fueron menores en el grupo con MLT respecto al control (P < 0,001). La actividad específica (mU/mg proteína) (P < 0,05) de GPx fue mayor en el grupo con MLT respecto al control. Se puede concluir que la administración de MLT a dosis de 3 mg/kg durante 15 días disminuyó el EOH inducido, de acuerdo a la concentración de MDA y DC. En el mismo sentido, la administración de la hormona redujo la hepatoesteatosis y aumentó la actividad de GPx. En este estudio se evidencia la acción protectora de la MLT; sin embargo, el mecanismo de acción a través del cual la hormona ejerce su actividad como antioxidante permanece en discusión. &nbsp

Published
2008

6. Probiotics in the add-on treatment of pharyngotonsillitis: A clinical experience

Author

La Mantia, I., Gelardi, M., Drago, L., Aragona, S. E., Cupido, G., Vicini, C., Berardi, C., Albanese, G., Anni, A., Antoniacomi, G., Artoni, S., Asprella, G., Azzaro, R., Azzolin, A., Balduzzi, A., Barbarino, I., Bertetto, B. I., Bianchi, A., Bianco, N., Bonanno, A., Bordonaro, C., Brindisi, A. M., Bucolo, S., Bulzomì, A. G., Caligo, G., Capaccio, P., Capelli, M., Capone, A., Carboni, S., Carluccio, G., Casaula, M., Cassano, M., Cavaliere, M., Ciabattoni, A., Conti, A., Cordier, A., Cortellessa, F., Costanzo, M., Cupido, F., D’ascanio, L., Danza, C., D’auria, C., Ciccio, M., Luca, C., D’emila, M., Dessi, R., Di Lullo, A., D’urso, M., Falcetti, S., Falciglia, R., Fera, G., Ferrari, G., Ferraro, S. M., Fini, O., Fiorella, M., Floriddia, A., Asprea, F., Fusco, C., Fuson, R., Gallo, A., Gambardella, T., Gambardella, G., Giangregorio, F., Gramellini, G., Ierace, M., Ingria, F., La Paglia, A., Lanza, L., Lauletta, R., Lavazza, P., Leone, M., Lovotti, P., Paolo Luperto, Maniscalco, F., Marincolo, I., Martone, R., Melis, A., Messina, A., Milone, V., Mirra, N., Montanaro, S. C., Muià, F., Nacci, A., Nardello, E., Paderno, L., Padovani, D., Palma, A., Paoletti, M., Pedrotti, I., Petrillo, F., Piccolo, M., Pinto, P., Policarpo, M., Raguso, M., Ranieri, A., Romano, G., Rondinelli, M., Russo, C., Di Santillo, L. S., Sequino, G., Serraino, E. M., Spahiu, I., Spanò, G., Stabile, C., Stagni, G., Stellin, M., Tassi, S., Tomacelli, G., Tombolini, A., Valenzise, V., and Zirone, A.

7. Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers

Author

Savastano, M., Marioni, G., Giacomelli, L., Ramonda, R., Ferraro, S. M., and LEONARDO PUNZI

Subjects
Adult, Male, Tumor Necrosis Factor-alpha, Hearing Loss, Sensorineural, Anti-Inflammatory Agents, Antibodies, Monoclonal, Middle Aged, Infliximab, Receptors, Tumor Necrosis Factor, Etanercept, Cohort Studies, Methotrexate, Immunoglobulin G, Humans, Female, Spondylitis, Ankylosing, Immunosuppressive Agents, Aged
Abstract

Sensorineural hearing loss (SNHL) in the uncommon disease ankylosing spondylitis (AS) has been previously reported. We analysed the relationships between AS, anti-TNF drug treatment, and SNHL.We determined pure tone thresholds in 28 consecutive patients with AS who were treated with the TNFalpha inhibitors etanercept or infliximab, or with a TNFalpha inhibitor plus methotrexate (MTX).SNHL was diagnosed in 16 patients (57.1%): 7/7 (100%) of those treated with anti-TNFalpha plus MTX, and 9/21 (43%) of those treated with anti-TNFalpha alone. We found a significant association between SNHL and treatment modality (p = 0.011) or treatment time in months (p = 0.020).The SNHL rate was significantly higher in patients treated with anti-TNFalpha plus MTX than those treated with anti-TNFalpha alone. The culpability of anti-TNF therapy was supported by the association between SNHL and treatment time, which was longer for anti-TNFalpha plus MTX than for anti-TNFalpha alone. SNHL may be due not only to AS, but also to drug-induced vasculitis of the labyrinthine artery or its cochlear branch.

8. Probiotics in the add-on treatment of laryngotracheitis: A clinical experience

Author

La Mantia, I., Gelardi, M., Drago, L., Salvatore Emanuele Aragona, Cupido, G., Vicini, C., Berardi, C., Ciprandi, G., Albanese, G., Anni, A., Antoniacomi, G., Artoni, S., Asprella, G., Azzaro, R., Azzolin, A., Balduzzi, A., Barbarino, I., Bertetto, B. I., Bianchi, A., Bianco, N., Bonanno, A., Bordonaro, C., Brindisi, A. M., Bucolo, S., Bulzomi, A. G., Caligo, G., Capaccio, P., Capelli, M., Capone, A., Carboni, S., Carluccio, G., Casaula, M., Cassano, M., Cavaliere, M., Ciabattoni, A., Conti, A., Cordier, A., Cortellessa, F., Costanzo, M., Cupido, F., D’ascanio, L., Danza, C., D’auria, C., Ciccio, M., Luca, C., D’emila, M., Dessi, R., Di Lullo, A., D’urso, M., Falcetti, S., Falciglia, R., Fera, G., Ferrari, G., Ferraro, S. M., Fini, O., Fiorella, M., Floriddia, A., Asprea, F., Fusco, C., Fuson, R., Gallo, A., Gambardella, T., Gambardella, G., Giangregorio, F., Gramellini, G., Ierace, M., Ingria, F., La Paglia, A., Lanza, L., Lauletta, R., Lavazza, P., Leone, M., Lovotti, P., Luperto, P., Maniscalco, F., Marincolo, I., Martone, R., Melis, A., Messina, A., Milone, V., Mirra, N., Montanaro, S. C., Muià, F., Nacci, A., Nardello, E., Paderno, L., Padovani, D., Palma, A., Paoletti, M., Pedrotti, I., Petrillo, F., Piccolo, M., Pinto, P., Policarpo, M., Raguso, M., Ranieri, A., Romano, G., Rondinelli, M., Russo, C., Di Santillo, L. S., Sequino, G., Serraino, E. M., Spahiu, I., Spano, G., Stabile, C., Stagni, G., Stellin, M., Tassi, S., Tomacelli, G., Tombolini, A., Valenzise, V., and Zirone, A.

9. Probiotics in the add-on treatment of otitis media in clinical practice

Author

Gelardi, M., La Mantia, I., Drago, L., Meroni, G., Salvatore Emanuele Aragona, Cupido, G., Vicini, C., Berardi, C., Ciprandi, G., Albanese, G., Anni, A., Antoniacomi, G., Artoni, S., Asprella, G., Azzaro, R., Azzolin, A., Balduzzi, A., Barbarino, I., Bertetto, B. I., Bianchi, A., Bianco, N., Bonanno, A., Bordonaro, C., Brindisi, A. M., Bucolo, S., Bulzomì, A. G., Caligo, G., Capaccio, P., Capelli, M., Capone, A., Carboni, S., Carluccio, G., Casaula, M., Cassano, M., Cavaliere, M., Ciabattoni, A., Conti, A., Cordier, A., Cortellessa, F., Costanzo, M., Cupido, F., D’ascanio, L., Danza, C., D’auria, C., Ciccio, M., Luca, C., D’emila, M., Dessi, R., Di Lullo, A., D’urso, M., Falcetti, S., Falciglia, R., Fera, G., Ferrari, G., Ferraro, S. M., Fini, O., Fiorella, M., Floriddia, A., Asprea, F., Fusco, C., Fuson, R., Gallo, A., Gambardella, T., Gambardella, G., Giangregorio, F., Gramellini, G., Ierace, M., Ingria, F., La Paglia, A., Lanza, L., Lauletta, R., Lavazza, P., Leone, M., Lovotti, P., Luperto, P., Maniscalco, F., Marincolo, I., Martone, R., Melis, A., Messina, A., Milone, V., Mirra, N., Montanaro, S. C., Muià, F., Nacci, A., Nardello, E., Paderno, L., Padovani, D., Palma, A., Paoletti, M., Pedrotti, I., Petrillo, F., Piccolo, M., Pinto, P., Policarpo, M., Raguso, M., Ranieri, A., Romano, G., Rondinelli, M., Russo, C., Di Santillo, L. S., Sequino, G., Serraino, E. M., Spahiu, I., Spanò, G., Stabile, C., Stagni, G., Stellin, M., Tassi, S., Tomacelli, G., Tombolini, A., Valenzise, V., Zirone, A., Gelardi, M., Mantia, La, Drago, I., Meroni, L., Aragona, G., Cupido, S. E., Vicini, G., Berardi, C., Ciprandi, C., Albanese, G., Anni, G., Antoniacomi, A., Artoni, G., Asprella, S., Azzaro, G., Azzolin, R., Balduzzi, A., Barbarino, A., Berardi, I., Bertetto, C., Bianchi, B. I., Bianco, A., Bonanno, N., Bordonaro, A., Brindisi, C., Bucolo, A. M., Bulzomì, S., Caligo, A. G., Capaccio, G., Capelli, P., Capone, M., Carboni, A., Carluccio, S., Casaula, G., Cassano, M., Cavaliere, M., Ciabattoni, M., Conti, A., Cordier, A., Cortellessa, A., Costanzo, F., Cupido, M., D’Ascanio, F., Danza, L., D’Auria, C., Ciccio, De, Luca, De, D’Emila, C., Dessi, M., Lullo, Di, D’Urso, A., Falcetti, M., Falciglia, S., Fera, R., Ferrari, G., Ferraro, G., Fini, S. M., Fiorella, O., Floriddia, M., Asprea, A., Fusco, F., Fuson, C., Gallo, R., Gambardella, A., Gambardella, T., Giangregorio, G., Gramellini, F., Ierace, G., Ingria, M., Paglia, La, Lanza, A., Lauletta, L., Lavazza, R., Leone, P., Lovotti, M., Luperto, P., Maniscalco, P., Marincolo, F., Martone, I., Melis, R., Messina, A., Milone, A., Mirra, V., Montanaro, N., Muià, S. C., Nacci, F., Nardello, A., Paderno, E., Padovani, L., Palma, D., Paoletti, A., Pedrotti, M., Petrillo, I., Piccolo, F., Pinto, M., Policarpo, P., Raguso, M., Ranieri, M., Romano, A., Rondinelli, G., Russo, M., Santillo, Di, Sequino, L. S., Serraino, G., Spahiu, E. M., Spanò, I., Stabile, G., Stagni, C., Stellin, G., Tassi, M., Tomacelli, S., Tombolini, G., Valenzise, A., and Zirone, V.

Subjects
chronic, Lactobacillu, Otitis Media, dysbiosi, Probiotics, Anti-Bacterial Agent, antibiotic therapy, acute, probiotic, Human
Abstract

Otitis media (OM) affects the middle ear and is typically characterized by earache. OM may be classified as acute (AOM) or chronic (COM), based on symptom duration. OM may be clinically suspected, but the diagnosis is usually confirmed by the otoscopy. Antibiotic therapy is frequently used in clinical practice. However, antibiotics often induce intestinal and respiratory dysbiosis associated with some clinical problems. A one-month course of a probiotic mixture (Abincol® containing Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 million living cells), and Lactobacillus delbrueckii LDD01 (200 million living cells), was prescribed in the Group A, and was compared with no addon treatment, such as the Group B. Patients were evaluated at baseline (T0), at the end of antibiotic treatment (T1), at the end of probiotic course (T2), and at the end of 3-month follow-up (T3).

10. Probiotics in the add-on treatment of rhinosinusitis: A clinical experience

Author

La Mantia, I., Gelardi, M., Drago, L., Aragona, S. E., Cupido, G., Vicini, C., Berardi, C., Ciprandi, G., Albanese, G., Anni, A., Antoniacomi, G., Artoni, S., Asprella, G., Azzaro, R., Azzolin, A., Balduzzi, A., Barbarino, I., Bertetto, B. I., Bianchi, A., Bianco, N., Bonanno, A., Bordonaro, C., Brindisi, A. M., Bucolo, S., Bulzomi, A. G., Caligo, G., Capaccio, P., Capelli, M., Capone, A., Carboni, S., Carluccio, G., Casaula, M., Cassano, M., Cavaliere, M., Ciabattoni, A., Conti, A., Cordier, A., Cortellessa, F., Costanzo, M., Cupido, F., D’ascanio, L., Danza, C., D’auria, C., Ciccio, M., Luca, C., D’emila, M., Dessi, R., Di Lullo, A., D’urso, M., Falcetti, S., Falciglia, R., Fera, G., Ferrari, G., Ferraro, S. M., Fini, O., Fiorella, M., Floriddia, A., Asprea, F., Fusco, C., Fuson, R., Gallo, A., Gambardella, T., Gambardella, G., Giangregorio, F., Gramellini, G., Ierace, M., Ingria, F., La Paglia, A., Lanza, L., Lauletta, R., Lavazza, P., Leone, M., Lovotti, P., Paolo Luperto, Maniscalco, F., Marincolo, I., Martone, R., Melis, A., Messina, A., Milone, V., Mirra, N., Montanaro, S. C., Muià, F., Nacci, A., Nardello, E., Paderno, L., Padovani, D., Palma, A., Paoletti, M., Pedrotti, I., Petrillo, F., Piccolo, M., Pinto, P., Policarpo, M., Raguso, M., Ranieri, A., Romano, G., Rondinelli, M., Russo, C., Di Santillo, L. S., Sequino, G., Serraino, E. M., Spahiu, I., Spano, G., Stabile, C., Stagni, G., Stellin, M., Tassi, S., Tomacelli, G., Tombolini, A., Valenzise, V., and Zirone, A.

11. Sensorineural hearing loss in ankylosing spondylitis treated with TNF blockers.

Author

Savastano M, Marioni G, Giacomelli L, Ramonda R, Ferraro SM, and Punzi L

Subjects
Adult, Aged, Cohort Studies, Etanercept, Female, Hearing Loss, Sensorineural diagnosis, Humans, Immunosuppressive Agents therapeutic use, Infliximab, Male, Methotrexate therapeutic use, Middle Aged, Spondylitis, Ankylosing complications, Anti-Inflammatory Agents therapeutic use, Antibodies, Monoclonal therapeutic use, Hearing Loss, Sensorineural epidemiology, Immunoglobulin G therapeutic use, Receptors, Tumor Necrosis Factor therapeutic use, Spondylitis, Ankylosing drug therapy, Tumor Necrosis Factor-alpha antagonists & inhibitors
Abstract

Objectives: Sensorineural hearing loss (SNHL) in the uncommon disease ankylosing spondylitis (AS) has been previously reported. We analysed the relationships between AS, anti-TNF drug treatment, and SNHL., Methodology: We determined pure tone thresholds in 28 consecutive patients with AS who were treated with the TNFalpha inhibitors etanercept or infliximab, or with a TNFalpha inhibitor plus methotrexate (MTX)., Results: SNHL was diagnosed in 16 patients (57.1%): 7/7 (100%) of those treated with anti-TNFalpha plus MTX, and 9/21 (43%) of those treated with anti-TNFalpha alone. We found a significant association between SNHL and treatment modality (p = 0.011) or treatment time in months (p = 0.020)., Conclusions: The SNHL rate was significantly higher in patients treated with anti-TNFalpha plus MTX than those treated with anti-TNFalpha alone. The culpability of anti-TNF therapy was supported by the association between SNHL and treatment time, which was longer for anti-TNFalpha plus MTX than for anti-TNFalpha alone. SNHL may be due not only to AS, but also to drug-induced vasculitis of the labyrinthine artery or its cochlear branch.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results